#USA #Fremont #Alzheimer's Disease #Alamar Biosciences #NULISAqpcr

Alamar Biosciences Launches NULISAqpcr™ AD 5-Plex

Alamar Biosciences, a pioneer in precision proteomics, has recently announced the introduction of their groundbreaking NULISAqpcr™ AD 5-plex test, aimed at advancing the detection of critical blood biomarkers for Alzheimer’s disease. This innovative assay quantifies five essential biomarkers from a single sample of blood or plasma, aligning with the recommendations from the Alzheimer’s Association.

Significant Technological Advancement

The NULISAqpcr™ AD 5-plex analysis captures key biomarkers including Brain-Derived Tau Phosphorylation (#tau217), Neurofilament Light Chain (NfL), Beta-amyloid 42 (Aβ42), Glial Fibrillary Acidic Protein (GFAP), and explores APOE4 carrier status. By offering these measurements simultaneously, the test provides unprecedented sensitivity and specificity for assessing amyloid pathology, tau pathology, neurodegeneration, and inflammation, which are integral to understanding Alzheimer’s progression.

Dr. Yuling Luo, founder, president, and CEO of Alamar Biosciences, expressed excitement about this release: "The launch of the NULISAqpcr AD 5-plex test is a significant milestone in our journey to provide precision proteomic solutions for neurodegenerative diseases. By merging these critical protein targets into a single assay and streamlining the workflow, we empower neuroscience researchers to enhance early screening, detection, and diagnostic accuracy for Alzheimer’s disease."

A Cost-Effective Solution

The NULISAqpcr™ test represents a paradigm shift in Alzheimer’s research, as Dr. Steven Williams, the Chief Scientific Officer at Alamar, elaborated: "Blood biomarkers are redefining Alzheimer’s research. They offer a precise, cost-effective, and accessible means for early diagnosis and to determine eligibility for therapies. Traditional single-plex tests require multiple distinct tests to paint a complete picture of the disease. With NULISA™, we can now measure various Alzheimer-related proteins from blood, each providing unique insights into the underlying pathophysiology."

This multifaceted approach not only offers greater ease of use for researchers but also facilitates a more comprehensive understanding of Alzheimer’s, ultimately aiding in the development of effective therapeutic strategies.

Broad Implications for Neurodegenerative Research

The NULISAqpcr AD 5-plex is designed to serve as a powerful research tool not only within Alzheimer’s research but also in the exploration of other neurodegenerative and cognitive disorders. Alamar’s commitment to collaboration with researchers, clinicians, and industry partners underscores its goal to enhance patient outcomes through precision proteomics.

The NULISAqpcr AD 5-plex test is currently available as a service through Alamar's technology access program. Interested parties can learn more about the test and view Alamar’s complete range of precision proteomic solutions by visiting www.alamarbio.com.

About Alamar Biosciences, Inc.

Alamar Biosciences is a private life sciences company dedicated to precision proteomics, enabling the early detection of diseases. Leveraging its proprietary NULISA™ technology and the ARGO™ HT system, Alamar’s platform is engineered to deliver ultra-sensitive measurements and overcome the limitations faced by existing technologies for precision proteomics. For further information, please visit alamarbio.com.